Success Stories: NAILG Helps an Organic Chemistry Postdoctoral Research Associate in Texas Secure an EB-1A Petition Approval (135 Citations, PP Upgrade, No RFE)

Client’s Testimonial:

“I am very excited to see your message. I am really very grateful to you all, especially Victoria Chen who handled my case most probably. You people are the best. The way I got help from you just amazing and no word to explain.”

On September 21^st, 2016, we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Research Associate in the Field of Organic Chemistry (Approval Notice).

General Field: Organic Chemistry

Position at the Time of Case Filing: Postdoctoral Research Associate

Country of Origin: India

Service Center: Texas Service Center (TSC)

State of Residence at the Time of Filing: Texas

Approval Notice Date: September 21^st, 2016

Processing Time: 56 Days (Premium Processing Requested)

Case Summary:

North America Immigration Law Group (NAILG) recently helped a postdoctoral research associate from India obtain an EB-1A (Alien of Extraordinary Ability) petition approval. His Ph.D. in Organic Chemistry and immense experience conducting scientific investigations ensured that he qualified for this visa category.

Proving that our client deserved to get closer to a green card:

We took on the challenge of proving to the USCIS that our client’s EB-1A petition deserved to be approved. Some of the information we included in his petition packet included data on his half a dozen published articles, the 30 times he conducted peer reviews, and the 135 times his findings were cited by other researchers in the field of organic chemistry. Not just that, we carefully reviewed his research projects on the development of new synthetic methodologies and the cutting-edge synthesis of novel drugs for medicinal chemistry and drug delivery. We demonstrated that our client’s work addresses some of the United States’ most pressing issues in treating some of the most lethal diseases and viruses, including cancer, SARS, and Ebola.

In a bid to bolster our client’s EB-1A petition, we urged him to contact other experts in the field and ask them to sign recommendation letters. Our client persuaded six of his peers to lend their support, and the recommendation letters they signed were incorporated into our client’s EB-1A petition dossier. They played an important role in proving to the USCIS that our client’s work is valued by members of the scientific community and that his efforts are extremely beneficial to the United States. This is what three of our client’s recommenders had to say about him and his work:

“As such, [Client’s] research has contributed substantial advancements to the field of organic chemistry and has improved the scientific community’s ability to perform organic reactions.

“Therefore, [Client’s] work on developing a cure is incredibly important not only to the United States, but to countries around the world.”

“[Client] is one of the most distinguished researchers engaged in organic chemistry and drug development today. Only a scant handful of fellow researchers in this field can boast similar records of success and acclaim, and as such [Client’s] work continues to be in high demand throughout the academic and medical spheres. These repeated successes in his past work provide a veritable guarantee that [Client] will continue to advance the field as a whole.”

We congratulate our client for attaining an EB-1A petition approval, and we thank him for selecting our law firm to represent his case. Furthermore, we wish him the best as he adjusts his status for permanent residence using our comprehensive I-485 D.I.Y. Packet.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.